Compare Medpace Holdings Inc (MEDP) vs Workiva Inc (WK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs Workiva Inc — how do they compare? Medpace Holdings Inc trades at $519.93 (market cap $15.08B), while Workiva Inc trades at $57.7 (market cap $3.21B). The key difference: Medpace Holdings Inc is far larger — about 4.7× Workiva Inc's market cap, and Medpace Holdings Inc is trading nearer its 52-week high, Workiva Inc nearer its low. Which is the better fit depends on your goals.
| MEDP | WK | |
|---|---|---|
Market Cap | $15.08B | $3.21B |
Sector | Technology | Technology |
52-Week High | $620.59 | $93.31 |
52-Week Low | $308.88 | $44.31 |
Enterprise Value | $14.55B | $3.14B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MEDP trades at $527.93, down 1.82% today, with a bullish technical outlook supported by moving averages. The company demonstrates strong profitability with 17.19% net margins and 77.25% ROE, though valuation ratios appear elevated with a P/E of 33.83. Recent earnings have consistently beaten expectations, and cash flow is projected to improve significantly in 2026. However, the stock faces headwinds from ongoing class action lawsuits and mixed analyst sentiment with 73.69% hold ratings.
MEDP presents a mixed investment case with strong fundamental performance offset by legal overhangs and premium valuation. The company's consistent earnings beats and projected cash flow improvement support upside potential, but investors should weigh the legal risks and cautious analyst stance against the robust operational metrics.
Workiva (WK) trades at $57.19, showing minimal daily movement with a 0.02% gain. The stock maintains a bullish technical outlook with strong analyst support (88.9% buy ratings) and a $71 consensus price target. Recent quarterly earnings consistently beat expectations, with Q1 2026 EPS of $0.77 surpassing the $0.66 estimate. Revenue growth continues with 2026 projections showing $926 million and a return to profitability at 1.53% net margin.
The outlook remains positive given Workiva's dominant market position in compliance software and AI-powered platform growth. Key risks include high valuation multiples (P/E 238.25) and competitive pressures in the enterprise software space. The stock offers 24% upside to consensus targets but requires monitoring of execution against elevated expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About Workiva Inc
Workiva is a leading provider of cloud-based platforms for complex reporting and compliance. It enables organizations to connect and manage data across financial reporting, ESG (Environmental, Social, and Governance), and GRC (Governance, Risk, and Compliance), serving as a single source of truth for auditable, transparent disclosures to regulators and stakeholders.
Read more on WK →
